Tscan Therapeutics Inc

TScan Therapeutics announced a strategic reorganization that includes a workforce reduction of approximately 75% as the company redirects resources toward an in vivo-engineered T cell receptor (TCR-T) program targeting solid tumors. The Waltham, Massachusetts-based company plans to advance two product candidates into investigational new drug-enabling studies, one targeting PRAME and the other targeting MAGE-A4. TScan expects to present preclinical data in the first quarter of 2027, submit its first investigational new drug application in the third quarter of 2027, and begin Phase 1 development in the fourth quarter of 2027. The reorganization is expected to generate cumulative cost savings of approximately $55 million through the end of 2027, and the company's cash, cash equivalents, and marketable securities as of June 30, 2026 are expected to fund operations into the fourth quarter of 2027. As part of the restructuring, TScan is eliminating its internal manufacturing organization and reducing its research operations. TScan is also pausing further enrollment in its Phase 3 ALLOHA-2 study of TSC-101 for hematologic malignancies, citing insufficient capital to complete the trial; seven patients already enrolled will continue to be monitored. The company is actively seeking strategic partners for its hematologic malignancies program and is evaluating partnerships for its autoimmune program focused on HLA-B*27-associated disorders. TScan also provided updated data from Cohort C of its Phase 1 ALLOHA study, showing that all 13 patients currently being followed demonstrated complete donor chimerism, including two who had previously relapsed. Additional Cohort C data are expected in the fourth quarter of 2026, and data covering all patients treated with its commercial-ready manufacturing process are expected in the second quarter of 2027.